Gene-silencing has featured in the news lately, with the approval of a new type of medicine for the treatment of a condition known as hereditary amyloidosis.
Gene-silencing treatment approved for hereditary amyloidosis Read More »
Ataxia UK is on the steering committee of these two Global Ataxia Schemes, which hope to advance clinical research into ataxia on a worldwide scale.
Leading gene therapy company uniQure have announced preclinical data on its gene therapy candidate, AMT-150, for the treatment of Spinocerebellar Ataxia 3 (SCA3).
uniQure releases new data from Spinocerebellar Ataxia Type 3 gene therapy study Read More »
The ‘New Modalities Ecosystem’, launched in 2018 by the Finnish pharmaceutical company Orion, aims to exploit Finnish expertise to deliver new treatments and technologies for rare diseases.
New initiative for rare diseases launched by Finnish pharmaceutical company Read More »
A recent study investigating the effect of investigating the effect of physiotherapy on patients with spinocerebellar ataxia type 7 (SCA7) has found that it to significantly improve symptoms.
Effects of physiotherapy in patients with spinocerebellar ataxia type 7 Read More »
Ataxia UK’s Head of Research Julie Greenfield reports on the 2018 Euro-ataxia annual conference held in Frankfurt.
Euro-ataxia annual meeting Read More »
We are delighted that on 20 February 2019 the Ataxia UK Medical Guidelines were published in the Orphanet Journal of Rare Diseases.
Ataxia UK medical guidelines published in peer-reviewed journal Read More »
We interview PhD student Wayne Yau about life as an ataxia researcher working on an Ataxia UK funded investigation on the role of genetic DNA repair mechanisms in a range of ataxias.
Interview with PhD student and ataxia researcher Wayne Yau Read More »
Euro-ataxia held the latest annual meeting on 9-10th November 2018 in Frankfurt, Germany, hosted by the German ataxia charity DHAG, organised by Ataxia UK and sponsored by BioMarin.
Euro-ataxia conference 2018 Read More »
NHS England has included hereditary ataxia in the final draft of the National Genomic Test Directory for rare and inherited disorders and cancer
Final draft of National Genomic Test Directory includes hereditary ataxia Read More »
Second trial investigating troriluzole in spinocerebellar ataxia announced by Biohaven pharmaceuticals to commence at the end of January.
SCA drug trial to begin in America Read More »
Catch up on the latest research news!
Research News – May and June 2018 Read More »
IntraBio, a U.K. based biopharmaceutical company, has received an Orphan Drug Designation from the US Food and Drug Administration (FDA) for its lead compound (IB1000) for the treatment of spinocerebellar
FDA Orphan Drug Designation for Spinocerebellar Read More »
Catch up on the Autumn’s latest research news.
Research News – October and November 2017 Read More »
Ataxia UK is working for the first time with the Spanish ataxia patient group R+SCAs (PLATAFORMA DE APOYO A LA INVESTIGACIÓN DE LAS ATAXIAS ESPINOCEREBELOSAS) in funding a research project
New partnership between Ataxia UK and the Spanish organisations R+SCAs and ACAH Read More »
Read up on the latest research news!
Latest Research News – March and April 2017 Read More »
Read up on the latest research news!
Latest Research News – January and February 2017 Read More »
Read up on the latest research news!
Latest Research News – December 2016 Read More »
the European Commission approves the first 23 European Reference Networks for rare diseases (ERNs), including the one covering the ataxias.
European Reference Networks Read More »
Read up on the latest research news!
Latest Research News – July and August 2016 Read More »
Read up on the latest research news!
Latest research news – May and June 2016 Read More »
